Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.2952W HIGH $40.65
Volume
792.25 K
Value Traded
11.53 M
Short % Float
21.58%
-2.25%Week
-9.27%1 Month
-39.02%3 Month
-43.36%6 Month
+8.6%5 Year
+8.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.19 B
EPS (TTM)
-2.16
P/E Ratio
-
Ent. Value
837.80 M
Total Shares
59.68 M
Float Shares
45.77 M
Insiders
23.30%
Institutions
96.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
TYRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Tyra Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tyra Biosciences, Inc.
136Total events
8Upcoming
18Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of $400 million underwritten offering of common stock and pre-funded warrants
●Oral PresentationPresentation
Tyra Biosciences to present at Cantor Global Healthcare Conference 2026
▲Topline ReadoutDabogratinibClinical Data
Initial Phase 2 SURF302 results for oral dabogratinib in LG IR NMIBC
FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)source ↗
▲Primary Endpoint MetDabogratinibClinical Data
SURF302 achieved 79% ORR and 64% BOR CR at 60 mg QD in combined marker lesion patients
FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)source ↗
▲Safety Data UpdateDabogratinibClinical Data
Favorable initial safety and tolerability results for dabogratinib in SURF302
FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)source ↗
▲Safety Data UpdateDabogratinibClinical Data
Initial safety and tolerability results from SURF302
FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)source ↗
▲Additional DataDabogratinibClinical Data
Initial efficacy results from SURF302
FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)source ↗
▲Dose Finding UpdateDabogratinibTrial
DSMC authorized opening of fifth dose level (0.625 mg/kg) in BEACH301
achondroplasia (ACH)source ↗
◆Topline ReadoutDabogratinibClinical Data
Interim results from safety sentinel cohort of BEACH301
achondroplasia (ACH)source ↗
◆Topline ReadoutDabogratinibClinical Data
Initial three-month complete response data from SURF302
intermediate risk non-muscle invasive bladder cancer (IR NMIBC)source ↗
◆Oral PresentationPresentation
TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
▲First Patient DosedDabogratinibTrial
Dosing patients with dabogratinib in Phase 2 SURF303 study for low-grade UTUC
low-grade UTUCsource ↗
●Poster PresentationDabogratinibPresentation
Preclinical results presented at Fusion Conference on FGFR Biology
ACHsource ↗
◆Topline ReadoutDabogratinibClinical Data
Interim results from safety sentinel cohort of BEACH301 expected
achondroplasiasource ↗
◆Poster PresentationDabogratinibPresentation
Poster presentation at ASCO GU 2026 of SURF301 mUC study data
metastatic urothelial cancer (mUC)source ↗
◆Topline ReadoutDabogratinibClinical Data
Initial three-month complete response data from SURF302 expected
low-grade intermediate risk non-muscle invasive bladder cancersource ↗
▲First Patient DosedDabogratinibTrial
First patient dosed in SURF303
low grade upper tract urothelial carcinoma (LG-UTUC)source ↗
●Poster PresentationDabogratinibPresentation
Poster presentations at ASCO GU and EAU 26
Urologic cancerssource ↗
▲Dose Finding UpdateDabogratinibTrial
DSMB authorized opening of fifth dose level (0.625 mg/kg) in BEACH301
achondroplasiasource ↗
▲First Patient DosedDabogratinibTrial
First patients dosed with dabogratinib in SURF302
low-grade intermediate risk non-muscle invasive bladder cancersource ↗
▲IND ClearanceDabogratinibIND
IND cleared with U.S. FDA for dabogratinib in LG-UTUC
low-grade upper tract urothelial carcinomasource ↗
▼Program DiscontinuationCorporate
Exited metastatic bladder cancer program
metastatic bladder cancersource ↗
▲First Patient DosedDabogratinibTrial
First patient dosed in Phase 2 NMIBC study SURF302
intermediate risk non-muscle invasive bladder cancer (IR NMIBC)source ↗
●Oral PresentationDabogratinibPresentation
Presented preclinical results at ENDO 2025
achondroplasia and hypochondroplasiasource ↗
▲First Patient DosedDabogratinibTrial
Dose first child with achondroplasia in BEACH301
achondroplasiasource ↗
▲Enrollment CompleteDabogratinibTrial
BEACH301 study open for enrollment
pediatric achondroplasiasource ↗
▲First Patient DosedTYRA-430Trial
Initiated patient dosing in SURF431 study of TYRA-430
hepatocellular carcinomasource ↗
◆First Patient DosedDabogratinibTrial
Dose first IR NMIBC patient with TYRA-300
intermediate risk non-muscle invasive bladder cancersource ↗
▲PublicationDabogratinibPresentation
Preclinical results with TYRA-300 published in JCI Insight
achondroplasiasource ↗
◆First Patient DosedTYRA-430Trial
Dose first HCC patient with TYRA-430
advanced hepatocellular carcinomasource ↗
◆First Patient DosedDabogratinibTrial
First child with achondroplasia expected to be dosed in BEACH301
achondroplasiasource ↗
◆Management ChangeCorporate
Chief Medical Officer transition plan announced; Hiroomi Tada to depart by end of year
Past FDA Catalysts and PDUFA Decisions
How TYRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-09 | oral dabogratinib | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$176M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 28%
Micro Cap(rank 185 of 658)
Percentile Rank
Tyra Biosciences, Inc. carries a moderate pipeline score (45/100), with $439M risk-adjusted pipeline value, led by Dabogratinib in Low Grade Upper Tract Urothelial Carcinoma (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dabogratinib Small moleculeNCT06842355 | Achondroplasia | Phase 2 | RECRUITING | 92 | Jun 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every TYRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| dabogratinib | low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC) | Phase 2 | 2026-09-09 | overall response rate: 79%; best overall response CR rate: 64%; single marker lesion ORR: 100%; single marker lesion CR rate: 75%; n: total 14, single marker 8Read More | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with DabogratinibRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Director, 10% Owner | Buy | 9,078,529 11,616,986 held | $22.03 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TYRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 3.4 % (-32 %) | 389.62 M | 12.20 M |
TYRA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TYRA ranks across every disease it competes in
Competitive Position is a premium feature
See how TYRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTYRA News
TYRA▲ +13.8%on this news
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tyra Biosciences has announced a $400 million underwritten offering of common stock and pre-funded warrants. The offering includes 9,079,000 shares priced at $22.03 each, with proceeds aimed at advancing its development strategy for various cancer treatments. The offering is expected to close on September 15, 2026, pending customary conditions.
Read more →TYRA▼ -17.7%on this newsshared move
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
Tyra Biosciences reported promising initial results from its Phase 2 SURF302 study of dabogratinib for low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study demonstrated a 79% overall response rate and favorable safety profile, supporting the drug's potential as a first-line oral treatment. The company plans to advance to a Phase 3 study based on these findings.
Read more →TYRA▼ -17.7%on this newsshared move
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
Tyra Biosciences, a clinical-stage biotechnology company, will present at the Cantor Global Healthcare Conference on September 9, 2026. The presentation will include a virtual fireside chat and one-on-one investor meetings. Tyra focuses on precision medicines targeting FGFR biology, with a pipeline that includes several investigational drugs for various cancers.
Read more →TYRA▲ +15.2%on this newsshared move
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Tyra Biosciences will host a conference call on September 9, 2026, to discuss initial results from the SURF302 Phase 2 study of oral dabogratinib for intermediate risk non-muscle invasive bladder cancer. This call will provide stakeholders with insights into the drug's performance and potential implications for treatment. The event will be accessible via a live webcast and telephone registration.
Read more →TYRA▼ -21%on this news
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences reported its second quarter 2026 financial results, highlighting upcoming clinical data from its SURF302 study on oral dabogratinib for bladder cancer. The company has a robust cash position of $353.9 million, ensuring operational continuity into 2028. Additionally, Jonathan Day was appointed as EVP of Clinical Development to bolster its skeletal dysplasia initiatives.
Read more →TYRATYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences has partnered with the Bladder Cancer Advocacy Network to establish Upper Tract Urothelial Cancer (UTUC) Awareness Day on May 21. This initiative aims to raise awareness of UTUC, a rare cancer with limited treatment options. The collaboration seeks to enhance patient support and highlight the need for innovative research in this area. Tyra is also advancing its investigational drug, dabogratinib, in clinical trials for UTUC.
Read more →TYRATyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - Advanced “ dabogratinib 3x3 ” strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG
Tyra Biosciences has reported its Q1 2026 financial results, highlighting the progress of its dabogratinib 3x3 strategy aimed at developing treatments for LG-UTUC, IR NMIBC, and achondroplasia. The company has dosed its first patient in the SURF303 trial, with significant initial results expected by 2027. They are also anticipating key data readouts from ongoing Phase 2 studies throughout 2026. Despite a net loss increase, Tyra's robust financial position is expected to support its clinical endeavors until at least late 2028.
Read more →TYRATyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, a clinical-stage biotechnology firm, announced its participation in several upcoming investor conferences, including the BofA Securities Health Care Conference and the Jefferies Global Healthcare Conference. These events will feature virtual and hybrid formats, allowing for direct engagement with investors. Tyra aims to highlight its innovative precision medicines targeting FGFR biology.
Read more →TYRATyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Tyra Biosciences has appointed Habib Dable to its Board of Directors, bringing over 30 years of biopharmaceutical leadership experience. Dable's background includes significant roles at Acceleron Pharma and Bayer AG, where he oversaw major product launches. His appointment is seen as pivotal for TYRA as it seeks to advance its pipeline and commercialize its FGFR3 inhibitor, dabogratinib.
Read more →TYRATyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Tyra Biosciences announced its financial results for Q4 and FY 2025, highlighting the launch of its 'dabogratinib 3x3' strategy aimed at advancing three late-stage clinical studies, targeting indications such as LG-UTUC, IR NMIBC, and ACH. The company reported a cash position of $256 million, ensuring operational support through 2027. Interim clinical data readouts for ongoing studies are expected in 2026. However, the company continues to incur losses, with Q4 2025 showing a net loss of $33.8 million amidst rising R&D expenses.
Read more →TYRATyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
Tyra Biosciences has reported its financial results for the third quarter of 2025, indicating significant advancement in its clinical trials for dabogratinib. The company has dosed its first patients in the BEACH301 and SURF302 studies while expanding dabogratinib's application to low-grade upper tract urothelial carcinoma. Although the company holds a strong financial position with $274.9 million in reserves, it continues to face increasing operating losses and expenses. Interim results from its studies are expected to be announced in 2026, which could validate the drug's broader potential.
Read more →TYRATyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Tyra Biosciences has reported its financial results for the second quarter of 2025, highlighting significant advancements including the dosing of the first patient in the SURF302 clinical trial for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The company's cash, cash equivalents, and marketable securities totaled $296.3 million, ensuring operational runway through at least 2027. In addition to SURF302, multiple clinical trials, including those for pediatric achondroplasia and advanced cancers, are currently advancing, supporting the firm’s focus on precision medications targeting FGFR biology.
Read more →TYRA▲ +10.3%on this news
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
Tyra Biosciences has reported substantial progress in its first quarter 2025 financial results, highlighting the opening of enrollment for the BEACH301 study of TYRA-300, targeting pediatric achondroplasia. The company also initiated dosing for its SURF431 study of TYRA-430 aimed at hepatocellular carcinoma. Financially, Tyra holds $318.9 million in cash and equivalents, providing a runway until at least 2027, despite experiencing increased net losses and rising research and development expenses. The advancements in clinical trials signify ongoing efforts in the development of next-generation precision therapies.
Read more →TYRA▼ -5.7%on this news
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
Tyra Biosciences announced significant advancements in its clinical pipeline and financial results for the year ending December 31, 2024. The company achieved FDA clearance for three Investigational New Drug applications for its precision small molecule TYRA-300, which is set to be evaluated in three Phase 2 studies. Financially, Tyra reported $341.4 million in cash, ensuring operational funding through at least 2027, although it also recorded a net loss increase year-over-year. Leadership transitions aim to strengthen the company's oncology strategies and clinical development.
Read more →TYRATyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of
Tyra Biosciences announced positive interim clinical results for its drug TYRA-300 in metastatic urothelial carcinoma (mUC) from the SURF301 Phase 1/2 study. The company also received IND clearance for a Phase 2 study of TYRA-300 in pediatric achondroplasia. Financial results for Q3 2024 show a net loss of $24.0 million, reflecting increased research and development expenses. Despite the losses, Tyra's cash reserves remain strong at $360.1 million, enabling continued development efforts.
Read more →TYRA▼ -23.3%on this news· ran to -44% by day 3
Today's participants and agenda AGENDA Introduction Todd Interim SURF301 TYRA-300 results Doug Q&A: Perspective of a leading Urologist Gary Todd Harris, PhD Doug Warner, MD Gary Steinberg, MD CEO, TYRA CMO, TYRA Professo
TYRA has presented interim clinical results for TYRA-300, an oral selective FGFR3 inhibitor, indicating promise in treating metastatic urothelial carcinoma (mUC). The treatment has shown anti-tumor activity and an improved safety profile compared to existing therapies. However, the results are preliminary and subject to change, underscoring the inherent risks and uncertainties involved in clinical trials and regulatory approvals.
Read more →TYRA▼ -23.3%on this news· ran to -44% by day 3shared move
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
Tyra Biosciences has reported interim clinical proof-of-concept data for TYRA-300, an investigational oral FGFR3-selective inhibitor, in its Phase 1/2 SURF301 study targeting metastatic urothelial cancer. The results show promising anti-tumor activity, with over half of the patients achieving a confirmed partial response. The safety profile appears favorable, with minimal associated toxicities.
Read more →TYRATyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights - SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstr
Tyra Biosciences reported its Q2 2024 financial results, highlighting significant advancements in their clinical pipeline. They achieved preclinical proof-of-concept for TYRA-300 aimed at hypochondroplasia and received IND clearance for TYRA-430 targeting hepatocellular carcinoma. The company also announced a transition in its Chief Medical Officer position and continues to maintain a robust cash position of $373.8 million. Despite a net loss increasing from the previous year, Tyra remains focused on their clinical studies and operational execution.
Read more →TYRATyra Biosciences Reports First Quarter 2024 Financial Results and Highlights - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and ma
Tyra Biosciences announced its first quarter 2024 financial results, reporting a net loss of $18.2 million. The company remains on track to submit an Investigational New Drug application for TYRA-300 in the second half of 2024, targeting treatments for achondroplasia and oncology. Recent board appointments may positively impact corporate governance. The company reported a healthy cash position of $382.5 million, ensuring operational funding through at least 2026.
Read more →TYRATyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submis
Tyra Biosciences has reported solid financial results for Q4 and the full year 2023, highlighting advancements in its pipeline, including the SURF301 Phase 1 oncology study and the ongoing development of TYRA-300 for achondroplasia. The company has successfully secured a $200 million private placement, enhancing its financial stability going into 2024. FDA grants of Rare Pediatric Disease and Orphan Drug Designations for TYRA-300 indicate significant progress in its targeted indications. However, despite these positive developments, the company also reported an increase in net loss and R&D expenses for the fourth quarter compared to the previous year.
Read more →About Tyra Biosciences, Inc.
Headquarters2656 STATE STREET, CARLSBAD, CA, 92008
BIOPHARMAWATCH ELITE PLUS
Trade the next TYRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime